Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butalbital is a barbiturate that potentiates GABA-A receptor activity, producing sedation; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, providing analgesic and antipyretic effects; caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy; codeine is an opioid agonist at mu-opioid receptors, producing analgesia via central mechanisms.
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Relief of tension-type headache symptoms (FDA-approved),Treatment of migraine headache (off-label)
Moderate to severe pain where an opioid analgesic is appropriate
1-2 capsules (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg) orally every 4 hours as needed, not to exceed 6 capsules per day.
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
Butalbital: 35-50 hours; Aspirin: 15-20 minutes (parent), salicylic acid: 2-3 hours at low doses, 15-30 hours at high doses; Caffeine: 3-7 hours; Codeine: 2.5-4 hours, morphine: 1.5-3.5 hours. Clinical context: Butalbital's long half-life contributes to prolonged sedation and risk of accumulation with repeated dosing.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Butalbital: hepatic via CYP2C19 and other CYP enzymes, partly excreted unchanged; aspirin: hydrolyzed to salicylate, conjugated in liver; caffeine: hepatic via CYP1A2 (major), CYP2E1, and CYP3A4; codeine: hepatic via CYP2D6 to morphine (active), CYP3A4 to norcodeine, and glucuronidation.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Codeine and its metabolites (morphine, codeine-6-glucuronide, norcodeine) are primarily excreted renally (>90%). Aspirin (acetylsalicylic acid) is hydrolyzed to salicylic acid, which is eliminated renally (75% as salicyluric acid, 10% as salicylic acid, 15% as other metabolites). Caffeine is largely metabolized in the liver and excreted renally (<3% unchanged). Butalbital is eliminated renally as metabolites and unchanged drug (about 60-70% as metabolites, 30-40% unchanged). Biliary/fecal elimination is minimal for all components.
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Butalbital: 20-30% (albumin); Aspirin: dose-dependent, 50-80% to albumin; Caffeine: 25-35% (albumin); Codeine: 20-25% (albumin).
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Butalbital: 0.5-0.6 L/kg; Aspirin: 0.15-0.2 L/kg; Caffeine: 0.6-1.0 L/kg; Codeine: 3-6 L/kg. Clinical meaning: High Vd for codeine indicates extensive tissue distribution.
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Oral: Butalbital ~90%; Aspirin 80-100% (first-pass hydrolysis to salicylic acid); Caffeine ~100%; Codeine ~60-90% (first-pass metabolism to morphine).
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
Cr Cl 10-50 m L/min: Administer at 75% of usual dose every 6 hours; Cr Cl <10 m L/min: Administer at 50% of usual dose every 6 hours.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; Child-Pugh Class C: Contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Not recommended for children under 12 years; for adolescents 12-18 years: 1 capsule orally every 4 hours as needed, not to exceed 4 capsules per day.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Initiate at lowest effective dose; consider reducing dose by 50% and extending interval to every 6 hours due to increased risk of respiratory depression, renal impairment, and aspirin-induced gastrointestinal bleeding.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
Risk of medication overuse headache; codeine: risk of addiction, abuse, misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and risks from concomitant use with benzodiazepines or other CNS depressants.
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Risk of Reye's syndrome with aspirin in children/viral illness; avoid exceeding recommended dosage due to rebound headache; GI bleeding risk with aspirin; opioid-induced respiratory depression, misuse, abuse, addiction; codeine use in children post-tonsillectomy/adenoidectomy; impaired alertness; risk of serotonin syndrome with serotonergic drugs; barbiturate dependence; caffeine withdrawal headache; hepatic/renal impairment; co-administration with alcohol or CNS depressants.
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Hypersensitivity to any component; pediatric patients with chickenpox or influenza-like illness (aspirin); significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; breastfeeding (codeine); concurrent use with MAOIs or within 14 days; porphyria (barbiturates).
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Avoid alcohol. High-fat meals may delay absorption. Avoid excessive caffeine intake from diet (coffee, tea, soda) to prevent additive stimulation. Maintain adequate hydration to reduce salicylate renal toxicity risk.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
First trimester: Aspirin associated with increased risk of gastroschisis; codeine may increase risk of congenital malformations (orofacial clefts, cardiac defects) based on some studies. Second trimester: Risk of miscarriage with NSAIDs; codeine not clearly associated. Third trimester: Aspirin and codeine associated with premature closure of ductus arteriosus, oligohydramnios, neonatal hemorrhage, and respiratory depression; butalbital may cause neonatal withdrawal. Overall: Combination product has multiple teratogenic components; avoid in pregnancy unless benefit outweighs risk.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Aspirin and caffeine are excreted in breast milk; codeine is excreted in low amounts but may cause CNS depression in infants, especially in CYP2D6 ultrarapid metabolizers. Butalbital is excreted in low amounts. M/P ratio: Not established for this combination; codeine M/P ratio approximately 0.2-0.4. Use with caution; monitor infant for sedation, respiratory depression, poor feeding.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Due to increased plasma volume and renal clearance in pregnancy, lower serum concentrations may occur. However, no specific dosing adjustments are recommended due to lack of data; use lowest effective dose for shortest duration. Avoid in third trimester if possible.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
Combination analgesic with opioid and non-opioid components. Hepatotoxicity risk from aspirin in children and adolescents (Reye syndrome). Measure serum salicylate and acetaminophen levels in overdose, but codeine is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy while ultra-rapid metabolizers risk toxicity. Avoid in patients with G6PD deficiency (aspirin-induced hemolysis). Caffeine may potentiate analgesia but also cause CNS stimulation and dependence. Prescribe with caution in elderly due to fall risk.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
This medication contains codeine, which can be habit-forming; use only as prescribed.,Do not take with other products containing acetaminophen, aspirin, or caffeine.,Avoid alcohol; may increase risk of liver damage and sedation.,Stop use and seek medical attention if you experience ringing in ears, severe nausea/vomiting, or signs of Reye syndrome (children).,Do not drive or operate machinery until you know how this drug affects you.,Keep out of reach of children; accidental overdose may be fatal.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
"Concurrent use of diphenhydramine and butalbital results in additive central nervous system (CNS) depression due to their overlapping sedative-hypnotic properties. Diphenhydramine, a first-generation antihistamine, antagonizes histamine H1 receptors and crosses the blood-brain barrier, while butalbital, a barbiturate, enhances GABA-A receptor activity. This synergism can lead to excessive sedation, impaired cognitive and motor function, respiratory depression, and increased risk of accidental injury or overdose, particularly in elderly patients or those with hepatic impairment."
"Agomelatine, a melatonergic antidepressant, combined with butalbital, a barbiturate and central nervous system (CNS) depressant, leads to additive CNS depression. This interaction increases the risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential overdose. Concurrent use may also alter hepatic metabolism via cytochrome P450 induction, reducing agomelatine efficacy and increasing butalbital toxicity."
"Amobarbital and Butalbital are both barbiturates that act as central nervous system (CNS) depressants. When co-administered, they exhibit additive CNS depression, leading to synergistic sedative and hypnotic effects, which can result in excessive sedation, respiratory depression, coma, or death. The combination significantly increases the risk of severe adverse outcomes, particularly in patients with compromised respiratory function or those taking other CNS depressants."
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Butalbital is a barbiturate that potentiates GABA-A receptor activity, producing sedation; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, providing analgesic and antipyretic effects; caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy; codeine is an opioid agonist at mu-opioid receptors, producing analgesia via central mechanisms.. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is: 1-2 capsules (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg) orally every 4 hours as needed, not to exceed 6 capsules per day.. The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE. The risk or severity of adverse effects can be increased when Pentazocine is combined with Butalbital. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is classified as Category D/X. First trimester: Aspirin associated with increased risk of gastroschisis; codeine may increase risk of congenital malformations (orofacial clefts, cardiac defects) based on some st. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.